Brazil
· Delayed Price · Currency is BRL BVMF: OFSA3 Company Description
Ouro Fino Saúde Animal Participações S.A., together with its subsidiaries, engages in the development, production, and sale of veterinary drugs, vaccines, and other products for production and companion animals primarily in Brazil.
The company operates through three segments: Production Animals, Companion Animals, and International Operations.
It manufactures and trades in medicines, including anti-inflammatories, antibiotics, anticoccidials, antimastitics, ectoparasiticides, endectocides, endoparasiticides, hemoparasiticides, inoculants, therapeutics, products for animal reproduction, and vaccines; and performance-enhancing additives, probiotics, and other veterinary products for cattle, swine, poultry, sheep, horses, and goats, as well as manufacturing services.
The company also manufactures veterinary solutions for dogs and cats, such as anesthetics, sedatives, anti-inflammatory, antibiotic, antimicrobial, dermatological, ectoparasiticide, endoparasiticide, dermocosmetic, and otological products.
In addition, it offers vaccines and other veterinary products for production and companion animals. The company was formerly known as A.H.N.S.P.E.
Empreendimentos e Participações S.A. Ouro Fino Saúde Animal Participações S.A. was incorporated in 1987 and is headquartered in Cravinhos, Brazil.
| Country | Brazil |
| Founded | 1987 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 1,202 |
| CEO | Kleber Cesar Gomes |
Contact Details
Address: Rodovia Anhanguera SP 330 Cravinhos, 14140-000 Brazil | |
| Phone | 55 16 3518 2025 |
| Website | ourofinosaudeanimal.com |
Stock Details
| Ticker Symbol | OFSA3 |
| Exchange | Brazil Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | BRL |
| ISIN Number | BROFSAACNOR7 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Kleber Cesar Silveira Gomes | Chief Executive Officer and Member of Executive Board |
| Marcelo Da Silva | Chief Financial Officer, Member of Executive Board and Chief Investor Relations Officer |
| Tetsuhiko Hiramatsu | Member of Executive Board |
| Angelo Melo | Director - Strategic Development and New Business |
| Bruno Menegazzo | Supervisor of the Investor Relations Area |